Dendreon's (DNDN) Provenge may be down in its battle with Zytiga, but its not out of the fight yet according to Baird. The firm notes that while Zytiga is still taking share, its momentum is declining. At present 20% of doctors indicate less Provenge use in favor of Zytiga. This figure is down from earlier readings of 31%, and 72% of physicians indicate no change, which is up from 63%. Baird feels that the Street has a much worse scenario priced into the shares, and reiterates its $7 price target.